- Characterizing the mechanisms of action and cell specificity underlying the anti-diabetic actions of lanthionine synthetase C-like 2 (LANCL2).
- Developing and refining novel animal models of type 2 diabetes and obesity.
- Characterizing novel classes of naturally occurring compounds with anti-diabetic and anti-inflammatory properties.
- Applying computational and mathematical modeling to integrate data and conceptual frameworks related to inflammatory and metabolic processes associated with type 2 diabetes. For instance modeling can be used to integrate metabolic and immunological data types.
- Apply bioinformatics and networks analyses approaches to identify novel therapeutic targets for metabolic and chronic inflammatory diseases.
- Investigating the cross-talk between immunity and metabolism in animal models that combine metabolic disease and infection.
Chronic diseases include metabolic inflammatory conditions such as obesity, diabetes, and cardiovascular disease. The NIMML is identifying and validating novel therapeutic targets for the treatment of obesity-related co-morbidities such as type-2 diabetes and developing lead compounds that can modulate these novel targets. Low-grade chronic inflammation is associated with overweight and obesity, type-2 diabetes and cardiovascular disease. The NIMML is identifying and validating novel therapeutic targets for the treatment of type-2 diabetes, and developing lead compounds that can modulate these novel targets.